Prothena is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for rare peripheral amyloid and neurodegenerative diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our diversified portfolio is designed to make a significant impact on rare peripheral amyloid.
Prothena’s success is driven by our people. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, except ourselves. Our values connect us – you will see and feel them come to life in all we do – together.
At Prothena, our culture reflects our values which are brought to life every day by the following characteristics:
Selfless
Patients come first and we’re in this together. Our environment is collaborative and we measure success through our collective accomplishments.
Courageous
Transformational innovation leads to novel treatments. “Tried-and-true” won’t produce breakthroughs for patients – a pioneering spirit, willingness to accept risk and try new approaches will. Each individual and team is expected to bring their heart, experience and trust on our journey.
Imaginative
We value and encourage a creative approach across all aspects of our work. We challenge ourselves and each other to think beyond what is known and approach our work through a lens of continuous improvement.
Joyful
Humor and heart allow us to tackle the seriousness of our work. Excellence and fun are not at odds – we love what we do and enjoy the journey.
For more information, please visit our website at http://www.prothena.com and follow us on Twitter @ProthenaCorp.
Prothena’s success is driven by our people. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, except ourselves. Our values connect us – you will see and feel them come to life in all we do – together.
At Prothena, our culture reflects our values which are brought to life every day by the following characteristics:
Selfless
Patients come first and we’re in this together. Our environment is collaborative and we measure success through our collective accomplishments.
Courageous
Transformational innovation leads to novel treatments. “Tried-and-true” won’t produce breakthroughs for patients – a pioneering spirit, willingness to accept risk and try new approaches will. Each individual and team is expected to bring their heart, experience and trust on our journey.
Imaginative
We value and encourage a creative approach across all aspects of our work. We challenge ourselves and each other to think beyond what is known and approach our work through a lens of continuous improvement.
Joyful
Humor and heart allow us to tackle the seriousness of our work. Excellence and fun are not at odds – we love what we do and enjoy the journey.
For more information, please visit our website at http://www.prothena.com and follow us on Twitter @ProthenaCorp.
Location: Ireland
Employees: 51-200
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 19
| Date | Title | Description |
| 09.09.2026 | Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | - |
| 06.08.2026 | Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and... |
| 30.07.2026 | Prothena to Report Second Quarter 2026 Financial Results on August 6 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and ... |
| 07.05.2026 | Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2... |
| 30.04.2026 | Prothena to Report First Quarter 2026 Financial Results on May 7 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2026 ... |
| 27.04.2026 | Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy | Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter antibody currently in Phase 3 development fo... |
| 09.03.2026 | Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyop... | Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial... |
| 27.02.2026 | Prothena Announces up to $100 Million Share Repurchase Plan | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized ... |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
| 12.02.2026 | Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and ... |
Show more